LTR Pharma (ASX:LTP) Secures Exclusive All-State U.S. Pharmacy Partner for ROXUS

Key Highlights

• LTR Pharma signs binding term sheet with Strive Pharmacy for exclusive U.S. pharmacy fulfilment rights for ROXUS

• Strive Pharmacy holds pharmacy licenses across all 50 U.S. states, enabling nationwide distribution

• Agreement follows LTR Pharma’s recent U.S. telehealth partnership targeting at least 150,000 prescriptions in the first year

• ROXUS is a rapid-acting intranasal erectile dysfunction treatment designed to work in 10 minutes or less

• Shares in LTR Pharma surged nearly 22.35% to $0.52 following the announcement

LTR Pharma completes another piece of its U.S. expansion puzzle

Just days after securing a major U.S. telehealth distribution agreement, LTR Pharma (ASX:LTP) has moved another step closer to commercial launch by locking in a nationwide pharmacy fulfilment partner for its flagship men’s health product, ROXUS.

The company has signed a binding term sheet with Strive Specialties Inc., better known as Strive Pharmacy, one of the United States’ established personalised medicine and compounding pharmacy operators.

The agreement grants Strive exclusive U.S. 503A pharmacy fulfilment rights for ROXUS, LTR Pharma’s proprietary intranasal spray developed for erectile dysfunction treatment.

For a company preparing to enter the world’s largest men’s health market, the deal effectively connects the final operational link between prescription generation and nationwide patient delivery.

Building a nationwide delivery network

The significance of the agreement lies in Strive Pharmacy’s reach.

The company holds pharmacy licences across all 50 U.S. states, allowing it to compound, package, dispense and ship personalised medications nationwide. Rather than spending years and significant capital building a pharmacy distribution network from scratch, LTR Pharma gains immediate access to an established and compliant infrastructure.

Under the arrangement, LTR Pharma will remain the owner of ROXUS, retaining intellectual property rights and supplying the formulation. Strive Pharmacy will handle compounding, fulfilment, regulatory compliance and direct-to-patient shipping.

The initial term runs for two years from commercial launch and automatically renews annually. Both parties are expected to finalise definitive agreements within 30 days.

Stock Price Movement

Shares of LTR Pharma (ASX:LTP) jumped 22.35% to $0.52 in morning trade on Thursday, June 11, after the company announced a binding partnership with U.S.-based Strive Pharmacy.

Source: MarketIndex 

Why ROXUS is attracting attention

The erectile dysfunction treatment market has undergone a major transformation over the past decade.

Telehealth providers have reshaped how patients access treatment, removing many of the barriers associated with traditional face-to-face consultations. At the same time, consumers have increasingly sought faster-acting and more convenient treatment options.

ROXUS aims to address that shift.

Unlike conventional oral erectile dysfunction medications that often require 30 to 60 minutes before becoming effective and can be affected by food or alcohol consumption, ROXUS uses a nasal delivery system designed to produce results within 10 minutes or less.

By bypassing the digestive system, the treatment seeks to offer a more predictable onset of action.

Industry analysts continue to point to strong growth in digital men’s health services globally as telehealth adoption expands and consumer preferences evolve toward discreet treatment options.

Momentum builds in the United States

The pharmacy agreement follows another significant milestone announced earlier this week.

On June 9, LTR Pharma revealed a commercial arrangement with a major U.S. telehealth provider that is targeting a minimum of 150,000 prescription units during its first year.

Together, the two agreements establish both the demand and fulfilment sides of the commercial model.

The company also recently reported positive Phase II clinical data for SPONTAN®, another asset within its intranasal treatment platform, helping strengthen confidence in the underlying technology.

Executive Chairman Lee Rodne said the Strive agreement represents a key launch-readiness milestone.

“Executing this binding term sheet with Strive Pharmacy materially advances our US commercialisation strategy for ROXUS. Securing an experienced national pharmacy fulfilment partner is an important launch-readiness milestone and provides the operational infrastructure required to support commercial launch activities. Combined with our broader patient acquisition and market access initiatives, the arrangement supports LTR Pharma’s planned multi-channel approach to commercialising ROXUS in the United States.”

Strive Pharmacy President and Co-Founder Michael Walker said the company sees strong potential in the product.

“We are excited to partner with LTR Pharma to support the introduction of ROXUS in the United States. ROXUS is an innovative addition to the men’s health category and aligns well with Strive Pharmacy’s focus on personalised medicine and patient-centric care.”

Looking ahead

For biotech companies, commercial execution is often more challenging than product development itself.

LTR Pharma now appears to have assembled key pieces of the U.S. commercial framework, from patient acquisition through telehealth channels to nationwide pharmacy fulfilment.

The next major milestone will be completing technology transfer processes and finalising definitive agreements before commercial launch activities commence.

If successfully executed, ROXUS could position LTR Pharma to participate in one of the fastest-growing segments of digital healthcare while leveraging a differentiated product designed around speed, convenience and patient experience.